The Immune Response Corporation

Rhone-poulenc Rorer Pharmaceuticals Inc.

Michael E. Hrinda

David M. Weber

Pierre M. Bay

James J. Harter

Immunization Products Limited

Jonathan J. Mitschelen

Thomas W. Irish

Christopher P. Prior

Richard S. Gore

George C. Tarr

James J Harter

Christopher P Prior

David M Weber

Richard S Gore

Michael E Hrinda

George C Tarr

Jonathan J Mitschelen

Pierre M Bay

Thomas W Irish

This invention is directed to a continuous process for producing viral particles comprising providing in a perfused growth medium a population of viable virally infected non-lytic cells, and removing medium containing said cells at a rate to maintain the steady-state log-phase growth of cells remaining in said perfused growth medium. The invention is also directed to a process for purifying retroviral particles comprising passing a solution comprising the retroviral particles and contaminants through an anion exchange resin, and eluting the retroviral particles from the resin.

Highly efficient production and isolation of viral particles utilizing

This invention is directed to a continuous process for producing viral particles by providing in a perfused growth medium a population of viable virally infected non-lytic cells, and removing medium containing said cells at a rate to maintain the steady-state log-phase growth of cells remaining in the perfused growth medium. The invention is also directed to a process for purifying retroviral particles by passing a solution comprising the retroviral particles and contaminants through an anion exchange resin, and eluting the retroviral particles from the resin. The preferred exchange resin is a tentacle anion exchange resin.

Production and purification of retroviral particles using tentacle anion

Growing community of inventors

Media, PA, United States of America

James J Harter